Evidence map›Paper›PMID 38135509›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

Parthenolide As a Therapeutic for Disseminated Canine Neoplasms.

Lisa J Schlein, Samuel A Brill, Rachel V Brady, Kristen B Farrell, Barbara J Rose, Travis K Meuten, Craig T Jordan, Douglas H Thamm

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lisa J SchleinFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.) Lisa.Schlein@colostate.edu.ORCID https://orcid.org/0000-0001-6117-0909
Samuel A BrillFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
Rachel V BradyFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
Kristen B FarrellFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).ORCID https://orcid.org/0000-0003-0476-6575
Barbara J RoseFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
Travis K MeutenFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
Craig T JordanFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
Douglas H ThammFlint Animal Cancer Center (L.J.S., S.A.B., R.V.B., K.B.F., B.J.R., T.K.M., D.H.T.) and Cell and Molecular Biology Graduate Program (L.J.S., S.A.B., R.V.B.), Colorado State University, Fort Collins, Colorado; and Anschutz Medical Campus, University of Colorado, Aurora, Colorado (C.T.J.).
University of Colorado Anschutz Medical Campus · US

Funding

Biomedical Research Training for VeterinariansT32OD010437 · OD · COLORADO STATE UNIVERSITY · PI Gregg A Dean, KELLY S SANTANGELO · 2012 to 2026
$6.2M
NRSA Training CoreTL1TR002533 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CICUTTO, LISA · 2018 to 2022
$3.0M
NCATS NIH HHS TL1 TR002533NIH HHS T32 OD010437
6 · The paper itself

Abstract

This study provides a unique translational research opportunity to help both humans and dogs diagnosed with diseases that carry dismal prognoses in both species: histiocytic sarcoma (HS), hemangiosarcoma (HSA), and disseminated mastocytosis/mast cell tumor (MCT). Although exceedingly rare in humans, these so called "orphan diseases" are relatively more common in dogs. For these and other more commonplace cancers like lymphoma (Lym), dogs are an excellent translational model for human disease due to remarkably similar disease biology. In this study, assays were performed to assess the therapeutic potential of parthenolide (PTL), a known canonical nuclear factor kappa B (NF-

Indexed as

HemangiosarcomaHistiocytic SarcomaSesquiterpenesAnimalsApoptosisCell Line, TumorDogsHumansMiceNF-kappa BNF-kappa BparthenolideSesquiterpenes

Identifiers

PMID38135509
PMCPMC10877710
OpenAlexW4390097209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.